- Report
- April 2025
- 200 Pages
Global
From €4229EUR$4,490USD£3,617GBP
- Report
- February 2025
- 200 Pages
Global
From €4229EUR$4,490USD£3,617GBP
- Report
- August 2024
- 138 Pages
Global
From €2825EUR$2,999USD£2,416GBP
- Report
- March 2022
- 198 Pages
Global
From €4192EUR$4,450USD£3,584GBP
- Report
- November 2023
- 30 Pages
Global
From €2590EUR$2,750USD£2,215GBP
- Report
- November 2023
- 30 Pages
Global
From €2590EUR$2,750USD£2,215GBP
- Report
- October 2023
- 145 Pages
Global
From €2967EUR$3,150USD£2,537GBP
- Report
- January 2023
- 156 Pages
Europe
From €3250EUR$3,450USD£2,779GBP
- Report
- April 2023
- 112 Pages
Global
From €4474EUR$4,750USD£3,826GBP
- Report
- June 2022
- 215 Pages
United States
From €2542EUR$2,699USD£2,174GBP
- Report
- October 2020
- 57 Pages
Global
- Report
- July 2018
- 224 Pages
Global
From €1272EUR$1,350USD£1,087GBP
€1696EUR$1,800USD£1,450GBP

Fluzone is a brand of influenza vaccine manufactured by Sanofi Pasteur, a global biopharmaceutical company. The vaccine is approved for use in individuals aged 6 months and older, and is available in both injectable and intranasal forms. It is designed to protect against the four most common strains of influenza virus. The vaccine is typically administered annually, usually in the fall, to provide protection against the flu season.
Fluzone is one of many influenza vaccines available on the market. Other brands include Afluria, Fluarix, Flucelvax, and Flublok. These vaccines are typically administered by healthcare providers in a doctor's office or clinic. In addition, some pharmacies and retail stores offer flu shots.
The market for influenza vaccines is highly competitive, with many companies offering similar products. Some of the major players in the market include Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more